Evolocumab enables rapid LDL-C reduction and inflammatory modulation during in-hospital stage of acute coronary syndrome: A pilot study on Chinese patients

Ziwei Ou1,2†, Zaixin Yu1†, Benhui Liang1, Lin Zhao2, Jianghua Li3, Xinli Pang3, Qiyun Liu3, Cong Xu3, Shaohong Dong3*, Xin Sun3* and Tangzhiming Li3*

†These authors share first authorship

Background and aims: Proprotein convertase subtilisin/kexin type 9 (PCSK9) has long been considered a key regulator in lipid metabolism. Its role as a potential player in immune response has recently earned much attention. However, the effects of evolocumab, an approved PCSK9 monoclonal antibody, on lipid reduction and inflammation regulation in Chinese patients with acute coronary syndrome (ACS) during their in-hospital stage after an index event are not well known.

Methods: We conducted a case-crossover pilot study (http://www.clinicaltrials.gov/, NCT04730648) involving 31 patients hospitalized for ACS with elevated low-density lipoprotein cholesterol (LDL-C) level (≥70 mg/dL despite high-intensity statin) and 8 age- and gender-matched patients without coronary heart disease (CHD) as the baseline control. The patients with ACS received one dose of subcutaneous evolocumab (140 mg) on top of 10 mg/day rosuvastatin during hospitalization. Blood samples at baseline and 72 h post-evolocumab administration were collected for lipid and cytokine assessments.

Results: The patients without CHD shared similar risk factors and LDL-C levels with the patients with ACS but exhibited a more activated inflammatory status. After single-dose in-hospital evolocumab, the median LDL-C level of patients with ACS decreased from 109.0 to 41.4 mg/dL as early as 72 h, accompanied with reductions in other atherogenic lipids. Systemic inflammatory pattern was also altered, rendering a decrease in pro-inflammatory and anti-inflammatory cytokines.

Conclusion: In this case-crossover study of the effect of PCSK9 antibody among Chinese patients, evolocumab on top of high-intensity statin during
hospitalization led to a remarkable and rapid reduction in atherogenic lipids and an alteration in inflammatory status at early-stage post-ACS.

KEYWORDS
evolocumab, acute coronary syndrome, atherogenic lipids, inflammatory cytokines, Chinese patients

Introduction

Current lipid management guidelines recommended the administration of high-intensity statin to patients with acute coronary syndrome (ACS) for the prevention of recurrent ischemic events (1, 2). However, the residual cardiovascular risk remains high in statin-treated patients with ACS, particularly at the early stage of a post-index event (3), owing to the sustained systemic inflammatory state and unsatisfactory low-density lipoprotein-cholesterol (LDL-C) level (4). Given the poor adherence to high-intensity statin therapy and the suboptimal lipid-lowering and inflammation-controlling effects of statins within 30 days after an index event in patients with ACS (5–8), new agents should be considered for acute use to reduce LDL-C and alleviate systemic inflammation more rapidly and potently.

Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a serine protease expressed in the liver and is known as a key regulator of low-density lipoprotein (LDL) metabolism. PCSK9 redundancy can induce LDL-C accumulation in the circulation and lead to hyperlipidemia by competitively binding to LDL receptor (LDLr) on the cell surface and subsequently causing LDLr internalization and degradation (9). In addition to lipid metabolism, PCSK9 is also associated with many other physiological processes (10), among which immune response is of great attention (11, 12).

A growing body of evidence has shown that neutralizing monoclonal antibodies against PCSK9, such as alirocumab and evolocumab, can reduce the long-term incidence of major adverse cardiovascular events (MACEs) in patients with established atherosclerotic cardiovascular disease (13–16). Recent studies also focused on the efficacy of LDL-C reduction with evolocumab in patients with ACS, supporting the benefit of the early initiation of PCSK9 monoclonal antibody for patients with ACS (17, 18). However, the effect of PCSK9 monoclonal antibody on inflammatory pattern during acute-phase post-ACS remains unclear, and little is known about the efficacy of evolocumab in the Chinese population.

Against this background, we conducted this pilot trial to assess the lipid-lowering and inflammation-regulating effects of the in-hospital use of evolocumab on top of high-intensity statin in Chinese patients with current ACS.

Methods

Study design and patients

This study (Acute Myocardial Infarction and Unstable Angina with PCSK9 Inhibitor Usage Study, AMONG-US) employed a case-crossover design and included patients with recent ACS (<1 week) whose LDL-C levels were higher than guideline-recommended targets (2) despite high-intensity statin (10 mg rosuvastatin) therapy. The protocol was approved by the institutional ethics committee of Shenzhen People’s Hospital, and all study subjects signed informed consent. The protocol and study design were prospectively described on ClinicalTrials.gov under the ID: NCT04730648. We complied with the guidelines of Consolidated Standards of Reporting Trials for clinical trials.

Screening was performed in hospitalized patients undergoing percutaneous coronary intervention (PCI) from April 2021 to December 2021 at the Department of Cardiology, Shenzhen People’s Hospital. Thirty-one patients with recent ACS were enrolled in the study. ACS diagnosis was based on clinical symptoms (i.e., chest pain), cardiac biomarker values (i.e., cardiac troponin), changes in electrocardiography, and intracoronary thrombus identified by angiography (19). Eight patients complaining about chest pain at admission with comparable principal risk factors but classified as non-coronary heart disease (CHD) after coronary angiogram evaluation were recruited as controls.

The study drug (evolocumab, Repatha®, 140 mg, single dose) was administered subcutaneously to patients with ACS after PCI as early as possible. The patients received rosuvastatin (10 mg/day) throughout the study.

Exclusion criteria

Patients with autoimmune diseases (e.g., Crohn’s disease, systemic lupus), recent infectious diseases, estimated glomerular filtration rate <30 mL/min/1.73 m², or under immunosuppressive drug therapy (e.g., oral steroids, non-steroidal anti-inflammatory agents, and cyclosporine) were excluded from this study.
Blood sample collection and laboratory

Fasting blood samples were obtained at baseline (before evolocumab administration) from all subjects and at 72 h post-evolocumab administration from the patients with ACS for the assessment of fasting lipids and circulating inflammatory markers. For measurement of fasting lipids, blood samples were collected and centrifuged at 4,000 × g for 5 min, and serum aliquots were stored at −80°C for further analysis. Serum LDL-C, high-density lipoprotein-cholesterol (HDL-C) and small dense low-density lipoprotein cholesterol (sdLDL-C) levels were measured directly using homogenous assay, and serum triglyceride (TG) and total cholesterol (TC) levels were detected using a direct colorimetric assay by the central laboratory of Shenzhen People's Hospital. Levels of Apolipoprotein B (ApoB), apolipoprotein E (ApoE) and apolipoprotein A1 (ApoA1) were measured via turbidimetric inhibition immunoassay.

For evaluation of circulating biomarkers, EDTA-anticoagulated blood samples were centrifuged within 30 min of collection at 3,000 × g for 10 min, and plasma aliquots were stored at −80°C until further analysis. The level of PCSK9 and two platelet activation markers in plasma, soluble P-selectin and platelet factor-4 (PF-4), were measured in duplicate using commercially available enzyme-linked immunosorbent assay kits (Cloud-Clone) per the manufacturer’s suggestion.

Bio-Plex Pro Human Cytokine 27-plex Immunoassay Kit (Bio-Rad), a human cytokine standard, was utilized to detect the plasma concentration of the following 27 cytokines based on the Luminex 200 system: interleukin-6 (IL-6), regulated upon activation normal T cell expressed and secreted factor (RANTES), vascular endothelial growth factor (VEGF), granulocyte-macrophage colony-stimulating factor (GM-CSF), interleukin-1 beta (IL-1β), interleukin-13 (IL-13), platelet-derived growth factor-BB (PDGF-BB),...
interleukin-12 p70 (IL-12p70), interleukin-1 receptor antagonist (IL-1ra), interleukin-10 (IL-10), interleukin-15 (IL-15), interferon gamma (IFN-γ), interleukin-5 (IL-5), monocyte chemotactic protein-1 (MCP-1), interleukin-2 (IL-2), interleukin-7 (IL-7), interleukin-8 (IL-8), eotaxin, interleukin-4 (IL-4), tumor necrosis factor alpha (TNF-α), macrophage inflammatory protein-1 beta (MIP-1β), interleukin-9 (IL-9), fibroblast growth factor basic (basic FGF), interleukin-17 (IL-17), interferon-inducible protein-10 (IP-10), macrophage inflammatory protein-1 alpha (MIP-1α), and granulocyte-colony stimulating factor (G-CSF).

Statistical analysis

Quantitative variables are shown as mean ± standard deviation (SD) for normally distributed data or median with interquartile range for abnormally distributed data. Student’s t-test or Mann–Whitney U-test was used for the comparison between two independent groups as appropriate. Wilcoxon matched-pairs signed rank test was used for the comparison between self-controlled paired groups. Categorical variables are shown as numbers and percentages, and Chi-square test was performed for comparisons. Statistical analysis was performed with GraphPad Prism 8, and figures were constructed with Adobe illustrator. P < 0.05 was considered statistically significant.

Results

Clinical characteristics of patients without CHD and patients with ACS

Out of 105 patients screened, 49 patients with ACS were approached for enrollment and received evolocumab (1 dose, 140 mg) during hospitalization. Thirty-one patients were included in this study based on information integrity, and eight were approached for enrollment and received evolocumab (1 dose, 140 mg) during hospitalization. Thirty-one patients were included in this study based on information integrity, and eight were approached for enrollment and received evolocumab (1 dose, 140 mg) during hospitalization.

Table 1

| Clinical characteristic | Non-CHD | ACS | P-value |
|-------------------------|--------|-----|---------|
| Age (years)             | 58 [55, 60] | 56 [48, 65] | 0.6020 |
| Male gender, n (%)      | 5 (63)  | 25 (81)  | 0.2775 |
| Body mass index (kg/m²) | 26.3 [23.3, 27.9] | 25.0 [23.4, 27.5] | 0.6889 |
| Diabetes mellitus, n (%)| 5 (63)  | 10 (32)  | 0.2202 |
| Arterial hypertension, n (%)| 4 (50)  | 19 (61)  | 0.5627 |
| Active smoking, n (%)   | 4 (50)  | 15 (48)  | 0.1782 |
| Statin treatment, n (%) | 8 (100) | 31 (100) | -      |
| eGFR (ml/min/1.73 m²)   | 86.9 ± 12.3 | 84.1 ± 28.8 | 0.7267 |
| Soluble P-selectin (ng/mL) | 28.67 [25.28, 32.16] | 26.03 [20.04, 33.06] | 0.4297 |
| Platelet factor-4 (ng/mL) | 0.95 [0.69, 1.28] | 1.38 [1.15, 1.65] | 0.0128 |
| TG (mg/dL)              | 139.1 [111.2, 194.9] | 152.4 [113.4, 217.1] | 0.6634 |
| TC (mg/dL)              | 159.5 [104.7, 209.3] | 159.1 [159.3, 221.9] | 0.0773 |
| HDL-C (mg/dL)           | 34.02 [26.39, 47.36] | 36.73 [32.86, 46.39] | 0.3965 |
| LDL-C (mg/dL)           | 92.59 [59.63, 127.0] | 109.0 [90.85, 144.6] | 0.1212 |

Data expressed as median [interquartile range], mean ± SD or number (percentage). Differences were tested using the Mann–Whitney test, unpaired t-test or Chi-square test, as appropriate.

CHD, coronary heart disease; ACS, acute coronary syndrome; eGFR, estimated glomerular filtration rate; TG, triglyceride; TC, total cholesterol; HDL-C, high density lipoprotein cholesterol; LDL-C, low density lipoprotein cholesterol.

Inflammatory patterns in non-CHD and ACS patients

A high-sensitivity 27-plex assay was performed for the measurement of the plasma concentrations of IL-6, RANTES, VEGF, GM-CSF, IL-1β, IL-13, PDGF-BB, IL-12p (70), IL-1ra, IL-10, IL-15, IFN-γ, IL-5, MCP-1, IL-2, IL-7, IL-8, eotaxin, IL-4, TNF-α, MIP-1β, IL-9, basic FGF, IL-17, IP-10, MIP-1α, and G-CSF in both groups of patients to assess the inflammatory status of patients with ACS. Surprisingly, chemokines, such as RANTES, eotaxin, IP-10, and MIP-1β (Figures 2B,C,H,K), and pro-inflammatory cytokines, including PDGF-BB, TNF-α, VEGF, IL-9, IL-17, and basic FGF (Figures 2D–J), were higher in patients without CHD compared with patients with ACS. Minor differences in other cytokines/chemokines were noted (Figure 2A), but none of them were statistically significant.

Accumulating evidence has implicated the importance of inflammation disorder in atheromatous plaque formation (20, 21). Therefore, the elevated circulating inflammatory factors in non-CHD patients should be considered a hint of the recruitment of activated macrophages, neutrophils, and T cells in the arterial wall during the premature stage of cardiovascular events. These findings suggested that the patients who came to the hospital because of chest pain but diagnosed as non-CHD...
Baseline plasma cytokine and chemokine levels in patients with non-CHD and ACS. Cytokine and chemokine levels were measured using Luminex assay in 8 patients without CHD and 31 patients with ACS. (A) Heat map of log2 fold changes in 27 analytes at baseline (corrected by the average levels in patients without CHD). (B–K) Differentially expressed analytes at baseline in patients with ACS compared with patients without CHD. Data are presented as medians with interquartile ranges. Differences were tested using Mann–Whitney U-test.

Single-dose evolocumab during hospitalization evidently attenuated lipid burden in patients with ACS

All patients with ACS in this study presented chest pain at admission and underwent PCI, and their blood samples were then collected at baseline (before evolocumab administration) and 72 h after single-dose evolocumab administration. To assess the rapid effect of single dose evolocumab on lipid metabolism and its potential effect on platelet activation, we measured the lipid profiles and platelet activation markers (Supplemental Figure 2), and the data are summarized in Table 2.

We observed a decrease of plasma PCSK9 in patients with ACS from 337.7 ± 83.3 ng/mL at baseline to 297.9 ± 85.8 ng/mL at 72 h post single-dose evolocumab (Supplemental Figure 1). The median LDL-C level of the patients with ACS was remarkably reduced from 109.0 to 41.4 mg/dL as early as 72 h after single-dose evolocumab, achieving a 60.5% average LDL-C reduction. The efficacy was comparable to previous evolocumab trials, where ~60% LDL-C reduction from baseline was reached on at least week 4 (13, 17, 18, 22, 23). Notably, evolocumab also remarkably diminished other atherogenic lipid particles, with average reductions of 18.1, 43.8, 60.6, and 49.5% in TG, TC, sdLDL-C, and ApoB, respectively. A remarkable decrease in ApoE, minor changes in ApoA1, and no remarkable difference HDL-C were found (Figure 3).

All patients with ACS were prescribed high-intensity statin therapy (rosuvastatin 10 mg/day) without regular evolocumab at discharge and 23 of them were successfully followed up. The median follow-up time was 10.7 months and the median LDL-C levels rebounded from 45.5 mg/dl at discharge to 70 mg/dL.
None of these patients experienced MACEs, liver or kidney dysfunction during our follow-up.

**Evolocumab altered inflammatory status in patients with ACS in the early period**

Given the rapid and evident effect of evolocumab in lipid burden reduction, and previous hypothesis on the anti-inflammation potential of PCSK9 inhibitors, the levels of circulating inflammatory biomarkers before and after evolocumab treatment in patients with ACS were compared.

As shown in **Figure 4**, pro-inflammatory cytokine IL-1β was significantly decreased after evolocumab administration compared with baseline (0.47 [0.35, 0.53] pg/mL vs. 0.72 [0.50, 1.14] pg/mL, \( P < 0.0001 \)), and a similar pattern was observed in IL-6 (1.11 [0.29, 3.63] pg/mL vs. 2.12 [0.68, 4.51] pg/mL, \( P = 0.0039 \)). IL-13 and IL-4, which are considered anti-inflammatory cytokines, were reduced as well after evolocumab treatment (0.61 [0.43, 0.96] pg/mL vs. 1.72 [0.79, 2.83] pg/mL at baseline, \( P < 0.0001 \) for IL-13; 2.59 [2.22, 3.14] pg/mL vs. 2.88 [2.13, 3.43] pg/mL at baseline, \( P = 0.0388 \) for IL-4).

**MCP-1**, a chemotactic molecule for monocytes/macrophages, was slightly downregulated (8.07 [6.79, 9.20] pg/mL vs. 9.20 [6.22, 12.19] pg/mL at baseline). A minor decrease was also noted in VEGF (0.06 [0.04, 0.10] pg/mL vs. 0.10 [0.06, 0.18] pg/mL at baseline, \( P = 0.0013 \)) and GM-CSF (0.46 [0.34, 0.53] pg/mL vs. 0.53 [0.46, 0.85] pg/mL at baseline, \( P = 0.0198 \)). No remarkable changes were observed in the remaining cytokines, including TNF-α and IFN-γ. The differentially expressed cytokines are summarized in **Table 3**.

**Discussion**

This study is one of the first studies focusing on immediate lipid-lowering efficacy and systematic inflammatory pattern changes mediated by the in-hospital use of evolocumab in Chinese patients with ACS. In our study, we showed that:

![Lipid profile](image-url)

**FIGURE 3**

Changes in lipid particles at 72 h post-evolocumab administration. Scattered plot of lipid profile data in **Table 2**. The dots of TG, TC, HDL-C, LDL-C, and sdLDL-C are aligned to the left Y axis, and the dots of Apo-A1, Apo-B, and Apo-E are aligned to the right Y axis. *\( P < 0.05 \), **\( P < 0.01 \), ****\( P < 0.0001 \). Differences were tested using Wilcoxon matched-pairs signed rank test. TG, triglyceride; TC, total cholesterol; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; sdLDL-C, small dense low-density lipoprotein cholesterol; Apo, apolipoprotein.
Comparison of plasma cytokine and chemokine levels between baseline and 72 h post-evolocumab administration in patients with ACS. Cytokine and chemokine levels were measured in 31 ACS patients using Luminex assay. (A) Heat map of log₂ fold changes over the average baseline levels of 27 analytes. (B–H) Differentially expressed cytokines and chemokines. Differences were tested using Wilcoxon matched-pairs signed rank test. Data are shown as actual concentrations (left) or medians with interquartile ranges of values normalized by baseline mean (right). UA, unstable angina; NSTEMI, non-ST-elevation myocardial infarction; STEMI, ST-elevation myocardial infarction.

1) The in-hospital use of single-dose evolocumab (140 mg) on top of high-intensity statin resulted in a universal reduction in atherogenic lipids as early as 72 h in patients with recent ACS, and

2) Treatment with evolocumab lowered the circulating levels of pro-inflammatory cytokines, such as IL-1β, IL-6, and MCP-1; anti-inflammatory cytokines, such as IL-13 and IL-4; and growth factors, such as GM-CSF and VEGF.

To date, the lipid management strategy for patients with ACS is stepwise and characterized by the initiation of high-intensity statin, succeeded by the addition of ezetimibe, and the administration of PCSK9 inhibitors only when the LDL-C level remains above the threshold (1, 2). Following this approach, PCSK9 inhibitors would not be considered until several months after an index event. However, the risk of recurrent ischemic events remains the highest during early post-ACS (24) probably because of the continued elevation of LDL-C...
TABLE 3  Concentrations and percentage changes of differentially expressed cytokines.

|                          | Baseline ($n = 31$) | Evolocumab ($n = 31$) | % Change from baseline | P-value   |
|--------------------------|---------------------|-----------------------|------------------------|-----------|
| **Pro-inflammatory cytokines** |                     |                       |                        |           |
| IL-1β (pg/ml)            | 0.72 [0.50, 1.14]   | 0.47 [0.35, 0.53]     | −37.7%                 | <0.0001   |
| (−49.2 to −14.6%)         |                     |                       |                        |           |
| IL-6 (pg/ml)             | 2.12 [0.68, 4.51]   | 1.11 [0.29, 3.63]     | −60.5%                 | 0.0309    |
| (−76.5 to −15.9%)         |                     |                       |                        |           |
| MCP-1 (pg/ml)            | 9.20 [6.22, 12.19]  | 8.07 [6.79, 9.20]     | −15.9%                 | 0.0408    |
| (−32.8 to 13.8%)          |                     |                       |                        |           |
| **Anti-inflammatory cytokines** |                   |                       |                        |           |
| IL-13 (pg/ml)            | 1.72 [0.79, 2.83]   | 0.61 [0.43, 0.96]     | −57.6%                 | <0.0001   |
| (−75.5 to −41.5%)         |                     |                       |                        |           |
| IL-4 (pg/ml)             | 2.88 [2.13, 3.43]   | 2.59 [2.22, 3.14]     | −10.1%                 | 0.0388    |
| (−19.6 to −2.2%)          |                     |                       |                        |           |
| **Growth factors**        |                     |                       |                        |           |
| GM-CSF (pg/ml)           | 0.53 [0.46, 0.85]   | 0.46 [0.34, 0.53]     | −26.1%                 | 0.0013    |
| (−30.6 to −13.2%)         |                     |                       |                        |           |
| VEGF (pg/ml)             | 0.10 [0.06, 0.18]   | 0.06 [0.04, 0.10]     | −40.0%                 | 0.0198    |
| (−60.0 to 0.0%)           |                     |                       |                        |           |

Data expressed as median (interquartile range) for cytokine concentrations and as median difference with 95% confidential interval for % change from baseline, respectively. Differences were tested using Wilcoxon matched-pairs signed rank test.

FIGURE 5  Short-term LDL-C-lowering efficacy of evolocumab in AMONG-US study and schematic diagram. Schematic diagram of the lipid-lowering and inflammation-regulating effects of evolocumab. The levels of TG, TC, LDL-C, sLDL-C, ApoA1, ApoB, and ApoE, as well as the circulating levels of IL-1β, IL-6, IL-4, IL-13, MCP-1, VEGF, and GM-CSF, decreased at 72 h post-evolocumab administration compared with baseline in patients with ACS.
level and overwhelming inflammation (25). Thus, a rapid lipid-lowering and inflammation-controlling approach is of great importance during acute-phase post-ACS.

The Evolocumab for Early Reduction of LDL Cholesterol Levels in Patients with Acute Coronary Syndromes study showed that the early initiation of evolocumab in patients with ACS exerted a more rapid and powerful LDL-C reduction within 4 weeks and enabled more than 95% patients to reach guideline-recommended LDL-C targets without considerable adverse events (17). Similarly, in the Evolocumab in Acute Coronary Syndrome study, patients with non-ST-elevation myocardial infarction (NSTEMI) who received one dose of evolocumab in the hospital exhibited a substantial decrement in LDL-C level from baseline within 1 day and a remarkable downward trajectory throughout their hospitalization (18). Consistently, in our study, early intervention with single-dose evolocumab (140 mg) remarkably alleviated the atherogenic lipid burden as early as 72 h. Notably, the reduction in LDL-C levels in our study reached 60% at day 3, which indicates that the immediate efficacy of evolocumab in our cohort was equivalent to that (at least 4 weeks after evolocumab administration) reported in other studies (13, 17, 18, 22, 23). This exciting finding may be attributed to the relatively low body mass index of Chinese people. We also observed a rebound in LDL-C levels when patients were treated with high-intensity statin alone during our follow-up, which indicates the single-use of evolocumab in addition to statins provides a rapid and strong but short-lived lipid-lowering effect.

Recent trials investigating anti-inflammatory agents in the secondary prevention of MACE have shed light on the advantages of inhibiting inflammation in patients with ACS (26, 27). In the Canakinumab Anti-Inflammatory Thrombosis Outcome Study, targeting IL-1β benefited patients with previous myocardial infarction (MI) in the view of non-fatal MI, non-fatal stroke, and cardiovascular death (26). Notably, among these patients, those who reached a lower level of IL-6 were even less vulnerable to MACEs (28). The Colchicine Cardiovascular Outcomes Trial revealed the protective role of colchicine for patients with recent MI in the aspect of recurrent MACEs by acting on multiple inflammatory pathways.

Previous studies showed that PCSK9 antibodies have no effect on circulating pro-inflammatory cytokines (29). Here, we observed a decrease in pro-inflammatory cytokines (IL-1β, IL-6, and MCP-1) and anti-inflammatory cytokines (IL-4 and IL-13) 72 h after evolocumab administration. Growth factors, VEGF and GM-CSF, which are considered pro-inflammatory (30, 31), declined as well shortly after evolocumab administration. These findings for the first time proved the impact of PCSK9 monoclonal antibody on systematic inflammatory cytokines for patients with recent ACS. Of interest, evolocumab switched the inflammatory status to a less aggressive stage, characterized by a lower level of pro- and anti-inflammation cytokines, implicating the potential role of PCSK9 antibody in regulating immune cell activation.

This preliminary study is limited by the cohort size and the lack of placebo comparison. Given the fact that all patients in this study were on high-intensity statin throughout their hospitalization, the net effect of evolocumab on LDL-C and other atherogenic lipids during this period was not clear. Besides, statins may be also partially involved in the switch of inflammatory status (32, 33). The clinical translation of our finding was also restricted because of the missing follow-up data after discharge. Further investigation on a larger population with placebo group is needed for a better understanding of the inflammation-regulating role of evolocumab at early-stage post-ACS.

Conclusion

The prompt use of evolocumab on top of high-intensity statin therapy during early post-ACS enabled patients to achieve rapid lipid burden reduction. Decreased circulating inflammatory cytokines were observed in the patients with ACS treated with evolocumab at early-stage post-index event, indicating a switch to systemic placid inflammatory status (Figure 5).

Data availability statement

The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.

Ethics statement

The studies involving human participants were reviewed and approved by Ethics Committee of Shenzhen People's Hospital. The patients/participants provided their written informed consent to participate in this study.

Author contributions

TL, SD, XS, LZ, JL, XP, QL, and CX contributed to conception and design of the study. ZO and TL carried out the experiment. ZO wrote the manuscript with support from ZY, TL, and BL. All authors contributed to manuscript revision, read, and approved the submitted version.
Funding

This research was supported by the National Natural Science Foundation of China (82000058, 82070517, 81873416, and 82070055), Key Research and Development Program of Hunan Province (2020SK065), Natural Science Foundation of Shenzhen (JCYJ20190807145051594), and Shenzhen People’s Hospital Research Cultivation Project (SYJCYJ202014 and SYLCYJ202119).

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

References

1. Grundy SM, Stone NJ, Bailey AL, Beam C, Birnkrant KK, Blumenthal RS, et al. 2018 AHA/ACC/AACVPR/APA/ABC/ACPM/ADA/AGS/APhA/ASPAC/NLA/PCNA guideline on the management of blood cholesterol: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. (2019) 139:e1046–e81. doi: 10.1161/CIR.0000000000000699
2. Mach F, Baigent C, Catapano AL, Koskinas KC, Casula M, Badimon L, et al. 2019 ESC/ESC Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. (2020) 41:111–88. doi: 10.15882/1560-4071-2020-3826
3. Brown TM, Bittner V, Colanattono LD, Deng L, Farkouh ME, Limdi N, et al. Residual risk for coronary heart disease events and mortality despite intensive medical management after myocardial infarction. J Clin Lipidol. (2020) 14:260–70. doi: 10.1016/j.jacl.2020.01.004
4. Dhindsa DS, Sandesara PA, Shapiro MD, Wong ND. The evolving understanding and approach to residual cardiovascular risk management. Front Cardiovasc Med. (2020) 7:86. doi: 10.3389/fcvm.2020.00088
5. Kim J, Lee HS, Nam CM, Heo JH. Effects of statin intensity and adherence on the long-term prognosis after acute ischemic stroke. Stroke. (2017) 48:2723–30. doi: 10.1161/STROKEAHA.117.018140
6. Klimis H, Chow CK. Clinical consequences of poor adherence to lipid-lowering therapy in patients with cardiovascular disease: can we do better? Heart Asia. (2019) 11:e011200. doi: 10.1136/heartasia-2019-011200
7. Armstrong PW, McAuley FA. Searching for adherence: can we fulfill the promise of evidence-based medicines? J Am Coll Cardiol. (2016) 68:802–4. doi: 10.1016/j.jacc.2016.06.006
8. Navar AM, Roe MT, White JA, Cannon CP, Pineda AL, Kanevsky E, et al. Low-density lipoprotein cholesterol lowering with evolocumab and outcomes in patients with peripheral artery disease: insights from the FOURIER trial (further cardiovascular outcomes research with PCSK9 inhibitors). Circulation. (2018) 137:338–50. doi: 10.1161/CIRCULATIONAHA.117.032235
9. Shapiro MD, Tavori H, Fazio S. PCSK9: from basic science discoveries to clinical trials. Circ Res. (2018) 122:1420–38. doi: 10.1161/CIRCRESAHA.118.311227
10. Cesaro A, Bianconi V, Gragnano F, Moscarella E, Fimiani F, Monda E, et al. Beyond cholesterol metabolism: the pleiotropic effects of proprotein convertase subtilisin/kexin type 9 (PCSK9). Genet Med Exp Perspect Long-term Inhibit. Biofogt. (2020) 8:367–80. doi: 10.1002/biof.1619
11. Liu X, Suo R, Chan CZY, Liu T, Tse G, Li G. The immune functions of PCSK9: Local and systemic perspectives. J Cell Physiol. (2019) 234:19180–8. doi: 10.1002/jcp.28612
12. Luqueiro A, Badimon L, Borrell-Pages M. PCSK9 functions in atherosclerosis are not limited to plasmatic LDL-cholesterol regulation. Front Cardiovasc Med. (2021) 8:639727. doi: 10.3389/fcvm.2021.639727
13. Sabatine MS, Giugliano RP, Wiviott SD, Ral JF, Blom DJ, Robinson J, et al. Efficacy and safety of evolocumab in reducing lipids and cardiovascular events. N Engl J Med. (2015) 372:1500–9. doi: 10.1056/NEJMoa1500858
14. Robinson JG, Farnier M, Krempf M, Bergeron J, Luc G, Averna M, et al. Efficacy and safety of alirocumab in reducing lipids and cardiovascular events. N Engl J Med. (2015) 372:1489–99. doi: 10.1056/NEJMoa1501033
15. Giugliano RP, Pedersen TR, Park JG, De Ferrari GM, Gaciong ZA, Ceska R, et al. Clinical efficacy and safety of achieving very low LDL-cholesterol concentrations with the PCSK9 inhibitor evolocumab: a prespecified secondary analysis of the FOURIER trial. Lancet. (2017) 390:1962–71. doi: 10.1016/S0140-6736(17)32290-0
16. Bonaca MP, Nault P, Giugliano RP, Keech AC, Pineda AL, Kanevsky E, et al. Low-density lipoprotein cholesterol lowering with evolocumab and outcomes in patients with peripheral artery disease: insights from the FOURIER trial (further cardiovascular outcomes research with PCSK9 inhibitors in subjects with elevated risk). Circulation. (2018) 137:338–50. doi: 10.1161/CIRCULATIONAHA.117.032235
17. Koskinas KC, Windecker S, Pedrazzini G, Mueller C, Cool S, Matter CM, et al. Evolocumab for early reduction of LDL cholesterol levels in patients with acute coronary syndromes (EVOPACS). J Am Coll Cardiol. (2019) 74:2452–62. doi: 10.1016/j.jacc.2019.08.030
18. Leucker TM, Blaha MJ, Jones SR, Vavourakis MA, Williams MS, Lai H, et al. Effect of evolocumab on atherogenic lipoproteins during the peri- and early postinfarction period: a placebo-controlled, randomized trial. Circulation. (2020) 142:419–21. doi: 10.1161/CIRCULATIONAHA.120.061320
19. Barstow C. Acute coronary syndrome: presentation and diagnostic evaluation. FF Essent. (2020) 490:11–9. Available online at: https://www.aafp.org/pubs/afp/issues/2017/0201/p170.html
20. Libby P, Hansson GK. From focal lipid storage to systemic inflammation: JACC review topic of the week. J Am Coll Cardiol. (2019) 74:1594–607. doi: 10.1016/j.jacc.2019.07.061
21. Lawler PR, Bhatt DL, Godoy LC, Luscher TF, Bonow RO, Verma S, et al. Targeting cardiovascular inflammation: next steps in clinical translation. Eur Heart J. (2021) 42:113–31. doi: 10.1093/eurheartj/ehaa099
22. Nicholls SJ, Puri R, Anderson T, Ballantyne CM, Cho I, Kastelein JJ, et al. Effect of evolocumab on progression of coronary disease in statin-treated patients: the GLAGOV randomized clinical trial. JAMA. (2016) 316:2573–84. doi: 10.1001/jama.2016.16951
23. Sabatine MS, Giugliano RP, Keech AC, Honarpour N, Wiviott SD, Murphy SA, et al. Evolocumab and clinical outcomes in patients with cardiovascular disease. *N Engl J Med.* (2017) 376:1713–22. doi: 10.1056/NEJMoa1615664

24. Schwartz GG, Olsson AG, Ezekowitz MD, Ganz P, Oliver ME, Waters D, et al. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study a randomized controlled trial. *JAMA.* (2001) 285:1711–8. doi: 10.1001/jama.285.13.1711

25. Gallone G, Baldetti L, Pagnesi M, Latib A, Colombo A, Libby P, et al. Medical therapy for long-term prevention of atherothrombosis following an acute coronary syndrome: JACC. state-of-the-art review. *J Am Coll Cardiol.* (2018) 72:2886–903. doi: 10.1016/j.jacc.2018.09.052

26. Ridker PM, Everett BM, Thuren T, MacFadyen JG, Chang WH, Ballantyne C, et al. Antiinflammatory therapy with canakinumab for atherosclerotic disease. *N Engl J Med.* (2017) 377:1119–31. doi: 10.1056/NEJMoa1707914

27. Tardif JC, Kour S, Waters DD, Bertrand OF, Diaz R, Maggioni AP, et al. Efficacy and safety of low-dose colchicine after myocardial infarction. *N Engl J Med.* (2019) 381:2497–503. doi: 10.1056/NEJMoa1912388

28. Ridker PM, Libby P, MacFadyen JG, Thuren T, Ballantyne C, Fonseca F, et al. Modulation of the interleukin-6 signalling pathway and incidence rates of atherosclerotic events and all-cause mortality: analyses from the Canakinumab Anti-Inflammatory Thrombosis Outcomes Study (CANTOS). *Eur Heart J.* (2018) 39:3499–507. doi: 10.1093/eurheartj/ehy310

29. Baruch A, Mosesova S, Davis JD, Budha N, Vilkoviskij A, Kahn R, et al. Effects of RG7652, a monoclonal antibody against PCSK9, on LDL-C, LDL-C subfractions, and inflammatory biomarkers in patients at high risk of or with established coronary heart disease (from the phase 2 EQUATOR study). *Am J Cardiol.* (2017) 119:1576–83. doi: 10.1016/j.amjcard.2017.02.020

30. Subramanian M, Thorp E, Tabas J. Identification of a non-growth factor role for GM-CSF in advanced atherosclerosis: promotion of macrophage apoptosis and plaque necrosis through IL-23 signaling. *Circ Res.* (2015) 116:e13–24. doi: 10.1161/CIRCRESAHA.116.304794

31. Sinnathamby T, Yun J, Clavet-Lanthier ME, Cheong C, Strois MG. VEGF and angiopoietins promote inflammatory cell recruitment and mature blood vessel formation in murine sponge/ Matrigel model. *J Cell Biochem.* (2015) 116:e13–24. doi: 10.1002/jcb.24941

32. Jain MK, Ridker PM. Anti-inflammatory effects of statins: clinical evidence and basic mechanisms. *Nat Rev Drug Discov.* (2005) 4:977–87. doi: 10.1038/nrd1901

33. Liberale L, Carbone F, Montecucco F, Sahebkar A. Statins reduce vascular inflammation in atherogenesis: a review of underlying molecular mechanisms. *Int J Biochem Cell Biol.* (2020) 122:105735. doi: 10.1016/j.biocel.2020.105735